CING earnings analysis
What we found in CING's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q excerpt does not disclose revenue, gross or operating margin, EPS, cash flow, balance-sheet amounts, or segment results, so quarterly operating trends cannot be quantified. Regulatory and manufacturing risks intensified after the June 2026 CRL for CTx-1301 and the February 2026 Form 483 containing 3 observations at the CDMO facility. Equity-for-debt issuances included 215,225 shares through July 7, 2026 and another 71,827 shares on August 10, 2026, indicating continued reliance on financing and dilution.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls remain effective
- Management concluded that disclosure controls were effective as of June 30, 2026, and reported no changes during the quarter that materially affected internal control over financial reporting.
- Debt converted into equity
- From May 11 through July 7, 2026, the company issued 215,225 shares to lenders in exchange for portions of debt, including 38,343 shares at $5.22, 55,928 at $4.47, and 53,030 at $3.96.
- Post-quarter debt settlement
- The company issued an additional 71,827 shares at $5.01 to a lender on August 10, 2026, after quarter-end, further reducing debt through equity settlement.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- CTx-1301 approval remains uncertain
- Cingulate received an FDA Complete Response Letter in June 2026 for its CTx-1301 NDA, citing CMC information requests and other non-clinical issues. The company stated that it plans to resubmit, but approval may be delayed, limited, or not obtained.
- CDMO inspection deficiencies
- The FDA conducted a pre-approval inspection of the CTx-1301 CDMO facility in February 2026 and issued a Form 483 containing 3 observations—2 facility-related and 1 specific to CTx-1301. A future re-inspection could identify additional deficiencies.
- Single-source manufacturing exposure
- All stages of the company's manufacturing process are currently completed by a single CDMO, and the filing states that Cingulate has no qualified alternative sources. Transferring production could require significant time and expense and create additional regulatory risk.
What they said about what is next.
The supplied 10-Q excerpt does not provide quantitative revenue, EPS, operating cash flow, or other financial guidance. No segment or income-statement data was included.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Cingulate's Q1 2026 results reflect a worsening net loss of $9.3 million compared to $3.9 million in Q1 2025, with no revenue reported. Operating expenses have surged significantly, particularly in general and…
- 10-K · March 18, 2026
- Cingulate is a clinical-stage biopharmaceutical company focused on its PTR timed‑release platform with lead ADHD candidate CTx-1301 (NDA submitted July 31, 2025 and accepted Sept 29, 2025). The filing reiterates a May…
- 10-Q · November 13, 2025
- Cingulate reported a Q3 2025 net loss of $(7,341,062) (EPS $(1.35)), compared with $(4,125,643) (EPS $(2.34)) in Q3 2024 and an EPS deterioration vs. the prior quarter (Q2 2025 EPS $(1.09) to $(1.35)). Cash declined to…
- 10-Q · August 19, 2025
- Cingulate remains a pre-revenue biopharma with no reported revenue and a Q2 2025 net loss of $4,788,735 (vs. $3,209,677 in Q2 2024). Cash declined to $8,900,183 as of June 30, 2025 and management states there is…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CING makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever